Chemotherapy is the primary treatment for triple-negative breast cancer (TNBC), and there's growing interest in targeting CD73 to enhance immunotherapy effectiveness, as it suppresses anti-cancer immunity.
CD73 carries a dual role in promoting tumor survival by both inhibiting immune response and enabling the growth of cancer stem cells (CSCs), which may lead to tumor relapse after treatment.
Researchers conducted in silico screening of compounds and found that quercetin and luteolin, when combined with the chemotherapy drug paclitaxel, effectively downregulated pathways associated with CD73 and CSCs, indicating a potential strategy for improved TNBC treatment outcomes.*
Systematic reviews on health equity often overlook differences in effectiveness across various equity factors, which hinders policy decisions.
A comprehensive search was conducted in multiple databases to identify studies that examine the methods used in systematic reviews for assessing health inequalities.
Health inequalities are defined as unfair differences in health outcomes related to social factors, and the study focused on analyzing these differences based on the PROGRESS-Plus framework, which includes various social determinants of health.